Impact of CVOTs in primary and secondary prevention of kidney disease

Salvatore De Cosmo, Francesca Viazzi, Pamela Piscitelli, Giovanna Leoncini, Antonio Mirijello, Barbara Bonino, Roberto Pontremoli

Research output: Contribution to journalReview articlepeer-review


Type 2 diabetes mellitus is the leading cause of end stage renal disease worldwide. Diabetic kidney disease, whose main clinical manifestations are albuminuria and decline of glomerular filtration rate, affects up to 40% of patients. Sodium Glucose cotransporter-2 inhibitors (SGLT2-is) and Glucagon-like peptide-1 receptor agonists (GLP-1ras) are new classes of anti-hyperglycemic drugs which have demonstrated to improve renal outcome. Renal benefits of both SGLT2-is and GLP-1ras are acknowledged from data of large randomized phase III clinical trials conducted to assess their cardiovascular safety. In this review, we will focus on renal results of major cardiovascular outcome trials, and we will describe direct and indirect mechanisms through which they confer renal protection.

Original languageEnglish
Article number107907
JournalDiabetes Research and Clinical Practice
Publication statusPublished - Nov 2019


  • Albuminuria
  • Glomerular filtration rate
  • Glucagon-like peptide-1 receptor agonists (GLP-1ras)
  • Sodium Glucose cotransporter-2 inhibitors (SGLT2-is)
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology


Dive into the research topics of 'Impact of CVOTs in primary and secondary prevention of kidney disease'. Together they form a unique fingerprint.

Cite this